---
title: Atrial Natriuretic Peptide in Assessing Fluid Status
nct_id: NCT05070819
overall_status: COMPLETED
phase: NA
sponsor: Petrovsky National Research Centre of Surgery
study_type: INTERVENTIONAL
primary_condition: Fluid Overload
countries: Russia
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05070819.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05070819"
ct_last_update_post_date: 2025-06-08
last_seen_at: "2026-05-12T06:30:28.085Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Atrial Natriuretic Peptide in Assessing Fluid Status

**Official Title:** Role of Atrial Natriuretic Peptide in Assessing of Fluid Status in Cardiac Surgery Patients

**NCT ID:** [NCT05070819](https://clinicaltrials.gov/study/NCT05070819)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 30
- **Lead Sponsor:** Petrovsky National Research Centre of Surgery
- **Conditions:** Fluid Overload, Fluid Loss, Volume Overload, Cardiac Disease, Cardiac Output, Low, Cardiac Output, High
- **Start Date:** 2021-09-23
- **Completion Date:** 2022-04-07
- **CT.gov Last Update:** 2025-06-08

## Brief Summary

Biomarkers can play a significant role in fluid status assessment intraoperatively.

## Detailed Description

Routinely intraoperatively the fluid status assessment is based on central venous pressure and other parameters. Nevertheless, the minority of anesthesiologists use continous dynamic parameters like pulse pressure variation, stroke volume variation and other to manage fluid status. There's a fast acting biomarker that can help anesthesiologist to diagnose and manage the volemic status and possibly guide the infusion therapy better.

Pro-ANP is a biomarker that reacts on atria strain and can be used in volemic status assessment in cardiac surgery patients.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 75 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

CABG, one-, two valve repair/replacement, ascending aorta, aortic arch replacement, ASD/AVD closure, septal myectomy

Exclusion Criteria:

1. Atrial fibrillation, atrial flutter, frequent ventricular and supraventricular arrythmias
2. EFLV \< 50%
3. Pulmonary hypertension \> 2 st
4. CKD \> C3 (GFR \< 30)
5. Redo surgery
6. Left atrium volume \> 150 ml
7. LV EDV \> 250 ml
```

## Arms

- **Cardiac surgery patients** (EXPERIMENTAL) — 1. After admission to OR and arterial catheter is placed the pro-ANP probe is obtained.
2. After anesthesia induction, trachea intubation before Teboul' test pro-ANP is obtained
3. At the end of Teboul' test when lower limbs are lifted
4. 30 minutes of CPB
5. End of CPB
6. End of volume transition from CPB circuit to patient
7. Before Teboul' test at the end of surgery
8. End of Teboul' test when lower limbs are lifted

## Interventions

- **pro-ANP** (DIAGNOSTIC_TEST) — pro-ANP samples and fluid status assessment with functional tests (Teboul test) will be used 8 times intraoperatively.

## Primary Outcomes

- **Number of Patients With Pro-ANP Twofold Raise by the End of Surgery** _(time frame: intraoperatively)_ — To assess the atria strain and consequent rise of pro-ANP by the end of surgery
- **Number of Patients With Pro-ANP Increase > 10% by the PLR Maneuver** _(time frame: intraoperative)_ — According to positive PLR the assessment of pro-ANP consequent raise
- **Number of Patients With Cardiac Index Rise > 10% After Passive Leg Raising Maneuver** _(time frame: 10 minutes of PLR test)_ — Using Massimo vigileo hard- and software the first assessment of cardiac index was made before Teboul test after the trachea intubation. After 10 minutes of passive leg raising maneuver second assessment. If raise in cardiac index above 10 percent was detected the patient was considered a responder. If not - non-responder.
- **Number of Patients With Pro-ANP Increase > 10% by the PLR Maneuver at the End of Surgery** _(time frame: 10 minutes of PLR test)_ — Using Massimo vigileo hard- and software the assessment of cardiac index was made before Teboul test at the end of surgery before leaving the operating room. After 10 minutes of passive leg raising maneuver second assessment. If raise in cardiac index above 10 percent was detected the patient was considered a responder. If not - non-responder.

## Secondary Outcomes

- **Postoperative Complications** _(time frame: up to 10 days)_
- **Mortality** _(time frame: up to 10 days)_
- **Multiorgan Failure** _(time frame: up to 10 days)_
- **Respiratory Failure** _(time frame: up to 10 days)_
- **Renal Failure** _(time frame: up to 10 days)_
- **Heart Failure** _(time frame: up to 10 days)_
- **Circulatory Insufficiency** _(time frame: up to 10 days)_
- **Infection Rate** _(time frame: up to 10 days)_
- **Length of Intensive Care Stay** _(time frame: up to 10 days)_

## Locations (1)

- Petrovsky Research National Centre of Surgery (Petrovsky NRCS), Moscow, Russia

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.petrovsky research national centre of surgery (petrovsky nrcs)|moscow||russia` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05070819.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05070819*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*